RS60592B1 - Nova imunoterapija za lečenje nekoliko tumora krvi, posebno hronične limfocitne leukemije (hll) - Google Patents

Nova imunoterapija za lečenje nekoliko tumora krvi, posebno hronične limfocitne leukemije (hll)

Info

Publication number
RS60592B1
RS60592B1 RS20200910A RSP20200910A RS60592B1 RS 60592 B1 RS60592 B1 RS 60592B1 RS 20200910 A RS20200910 A RS 20200910A RS P20200910 A RSP20200910 A RS P20200910A RS 60592 B1 RS60592 B1 RS 60592B1
Authority
RS
Serbia
Prior art keywords
peptide
cells
peptides
hla
cell
Prior art date
Application number
RS20200910A
Other languages
English (en)
Serbian (sr)
Inventor
Juliane Stickel
Daniel Kowalewski
Hans-Georg Rammensee
Stefan Stevanovic
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of RS60592B1 publication Critical patent/RS60592B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RS20200910A 2014-06-20 2015-06-17 Nova imunoterapija za lečenje nekoliko tumora krvi, posebno hronične limfocitne leukemije (hll) RS60592B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462014849P 2014-06-20 2014-06-20
GBGB1411037.3A GB201411037D0 (en) 2014-06-20 2014-06-20 Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
EP15730135.9A EP3157549B1 (en) 2014-06-20 2015-06-17 Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
PCT/EP2015/063566 WO2015193359A2 (en) 2014-06-20 2015-06-17 Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)

Publications (1)

Publication Number Publication Date
RS60592B1 true RS60592B1 (sr) 2020-08-31

Family

ID=51409910

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200910A RS60592B1 (sr) 2014-06-20 2015-06-17 Nova imunoterapija za lečenje nekoliko tumora krvi, posebno hronične limfocitne leukemije (hll)

Country Status (14)

Country Link
EP (2) EP3708185A3 (enExample)
JP (1) JP6560261B2 (enExample)
CA (1) CA2950827A1 (enExample)
DK (1) DK3157549T3 (enExample)
ES (1) ES2802155T3 (enExample)
GB (1) GB201411037D0 (enExample)
HU (1) HUE050070T2 (enExample)
LT (1) LT3157549T (enExample)
PL (1) PL3157549T3 (enExample)
PT (1) PT3157549T (enExample)
RS (1) RS60592B1 (enExample)
SI (1) SI3157549T1 (enExample)
TW (3) TW202024125A (enExample)
WO (1) WO2015193359A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
JP7174627B2 (ja) 2015-10-23 2022-11-17 ウニフェルシタイト・トゥヴェンテ インテグリン結合ペプチド及びその使用
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
CN114028549A (zh) 2016-02-19 2022-02-11 伊玛提克斯生物技术有限公司 用于nhl和其他癌症免疫治疗的新型肽和肽组合物
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
MA54832A (fr) 2016-03-01 2021-12-01 Immatics Biotechnologies Gmbh Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
GB201603987D0 (en) * 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
CR20200608A (es) 2016-04-21 2021-01-20 Immatics Biotechnologies Gmbh INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0551)
SG11201808629UA (en) 2016-04-21 2018-11-29 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
DE102016005550B4 (de) 2016-05-09 2024-09-26 Hans-Georg Rammensee Adjuvans zur lnduzierung einer zellulären lmmunantwort
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
CN106046130B (zh) * 2016-07-07 2017-12-12 胡国田 一种多肽及其应用
TWI796299B (zh) 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EA201992416A1 (ru) 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
CN111533799A (zh) 2017-04-10 2020-08-14 伊玛提克斯生物技术有限公司 用于白血病和其他癌症免疫治疗的肽和肽组合物
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
WO2020035123A1 (en) * 2018-08-11 2020-02-20 Baerlecken Niklas Autoantibodies binding to negative elongation factor e (nelf-e) for diagnosing sarcoidosis
CN109593125A (zh) * 2018-12-12 2019-04-09 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p1及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IN151589B (enExample) 1978-12-22 1983-05-28 Biogen Nv
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
DE60142475D1 (de) 2000-03-27 2010-08-12 Technion Res And Dev Of Founda Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung
US20030144474A1 (en) 2000-06-05 2003-07-31 Sunol Molecular Corporation T cell receptor fusions and conjugates and methods of use thereof
US20040053292A1 (en) * 2000-11-15 2004-03-18 Jurg Tschopp Proteins and dna sequences underlying these proteins used for treating inflammations
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
WO2005114221A2 (en) * 2004-05-21 2005-12-01 The Institute For Systems Biology Compositions and methods for quantification of serum glycoproteins
PL1760088T3 (pl) 2005-09-05 2008-10-31 Immatics Biotechnologies Gmbh Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2012056407A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors

Also Published As

Publication number Publication date
DK3157549T3 (da) 2020-06-22
WO2015193359A3 (en) 2016-02-25
EP3157549A2 (en) 2017-04-26
JP2017525336A (ja) 2017-09-07
JP6560261B2 (ja) 2019-08-14
TW201613956A (en) 2016-04-16
ES2802155T3 (es) 2021-01-15
EP3708185A2 (en) 2020-09-16
HUE050070T2 (hu) 2020-11-30
GB201411037D0 (en) 2014-08-06
EP3157549B1 (en) 2020-04-29
PT3157549T (pt) 2020-07-01
EP3708185A3 (en) 2020-11-04
CA2950827A1 (en) 2015-12-23
WO2015193359A2 (en) 2015-12-23
TW201930347A (zh) 2019-08-01
TWI670282B (zh) 2019-09-01
LT3157549T (lt) 2020-08-10
PL3157549T3 (pl) 2020-12-14
SI3157549T1 (sl) 2020-08-31
TW202024125A (zh) 2020-07-01

Similar Documents

Publication Publication Date Title
EP3157549B1 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
US10875892B2 (en) Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
RS59471B1 (sr) Nova imunoterapija za lečenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
RS61713B1 (sr) Peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raka prostate i drugih malignih tumora
AU2022203259B2 (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
WO2020025576A1 (en) Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods
US11058755B2 (en) A*03 restricted peptides for use in immunotherapy against cancers and related methods
US20200325192A1 (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
WO2020058285A1 (en) B*44 restricted peptides for use in immunotherapy against cancers and related methods
WO2020058360A1 (en) Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods
CA3108747A1 (en) Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods
JP2020014460A (ja) 数種の血液腫瘍、特に慢性リンパ性白血病（ｃｌｌ）に対する新規免疫療法
HK1236424B (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
HK1236424A1 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
HK1232240B (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
HK1232240A1 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)